Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
TOKYO, Feb 28, 2023 – (J […]
HIROSHIMA, Japan, Feb 28, 2023 […]
TOKYO, Feb 27, 2023 – (J […]
Toyota City, Japan, Feb 27, 20 […]
SUNNYVALE, Calif., and TOKYO, […]
TOKYO, Feb 27, 2023 – (J […]
TOKYO, Feb 27, 2023 – (J […]
TOKYO, Feb 24, 2023 – (J […]
TOKYO, Feb 24, 2023 – (J […]
TOKYO and SEOUL, Feb 24, 2023 […]
ZURICH, SWITZERLAND, Feb 23, 2 […]
TOKYO, Feb 22, 2023 – (J […]
TOKYO, Feb 22, 2023 – (J […]
Los Angeles & Tokyo, Feb 2 […]